# An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

> **NCT07324889** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Yihao Wang** · enrollment: 24 (estimated)

## Conditions studied

- Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** CD19/BCMA CAR-T

## Key facts

- **NCT ID:** NCT07324889
- **Lead sponsor:** Yihao Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07324889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07324889, "An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07324889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*